Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion -…
stemadminMesenchymal Stem CellsNo comments

Gosselies, Belgium, 14 October 2020, 7am CEST BONE THERAPEUTICS(Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces positive 24-month follow-up results for the Phase IIa study with the allogeneic cell therapy product, ALLOB, in patients undergoing lumbar spinal fusion procedures. The 24-month data show a high percentage of successful lumbar vertebrae fusion of 90%. Patients also continue to experience important clinical improvements in function and pain, from as early as six months after treatment, up to the 24-month follow-up period.

Read more
Citius Pharmaceuticals : Signs an Exclusive Worldwide Licensing Agreement with Novellus Therapeutics for Unique iMSC-Therapy – marketscreener.com
stemadminMesenchymal Stem CellsNo comments

CRANFORD - Citius Pharmaceuticals, Inc. ('Citius' or the 'Company') (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, announced that it has signed an exclusive agreement with Novellus Therapeutics Limited ('Novellus') to license iPSC-derived mesenchymal stem cells (iMSCs), and has created a new subsidiary, NoveCite, that will be focused on developing cellular therapies. NoveCite has a worldwide exclusive license from Novellus, an engineered cellular medicines company, to develop and commercialize NoveCite mesenchymal stem cells ('NC-iMSCs') to treat acute respiratory conditions with a near term focus on Acute Respiratory Distress Syndrome ('ARDS') associated with COVID-19

Read more
Global Mesenchymal Stem Cells by leading manufacturers with its application and types 2020-2026| Lonza, Celprogen, ATCC – re:Jerusalem
stemadminMesenchymal Stem CellsNo comments

Mesenchymal Stem Cells Market Report Delivering Growth Analysis with Key Trends of Top Companies (2020-2026) A comprehensive research study on the Mesenchymal Stem Cells Marketwas recently published by Market Report Expert. This is an up-to-date report, covering the current COVID-19 impact on the market. The Coronavirus (COVID-19) has affected every aspect of life globally and thus altering the global market scenario

Read more
Citius Pharma inks license pact with Novellus for stem cell therapy in respiratory distress – Seeking Alpha
stemadminMesenchymal Stem CellsNo comments

Citius Pharmaceuticals (NASDAQ:CTXR) has exercised its previously announced option agreement, andannounced an exclusive agreement with Novellus Therapeutics to license iPSC-derived mesenchymal stem cells (iMSCs). The company has created a new subsidiary, NoveCite, that will focus on development and commercialization of NoveCite mesenchymal stem cells (NC-iMSCs) for the treatment of acute respiratory conditions with a near term focus on Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19.

Read more

Theme: Illdy.